Kezar Life Sciences/KZR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Kezar Life Sciences

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.

Ticker

KZR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Christopher Kirk

Employees

58

Headquarters

South san francisco, United States

KZR Metrics

BasicAdvanced
$51M
Market cap
-
P/E ratio
-$1.40
EPS
0.22
Beta
-
Dividend rate
$51M
0.2247
$3.13
$0.67
703K
11.663
5.368
5.368
-39.12%
-44.54%
-41.41%
7.218
0.269
0.269
-38.30%

What the Analysts think about KZR

Analyst Ratings

Majority rating from 6 analysts.
Buy

KZR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-100.00%
Net income
-$32M
39.39%
Profit margin
0.00%
-100.00%

KZR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.86%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.34
-$0.32
-$0.44
-$0.30
-
Expected
-$0.32
-$0.35
-$0.38
-$0.33
-$0.32
Surprise
6.25%
-8.35%
15.85%
-9.86%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Kezar Life Sciences stock?

Kezar Life Sciences (KZR) has a market cap of $51M as of June 14, 2024.

What is the P/E ratio for Kezar Life Sciences stock?

The price to earnings (P/E) ratio for Kezar Life Sciences (KZR) stock is 0 as of June 14, 2024.

Does Kezar Life Sciences stock pay dividends?

No, Kezar Life Sciences (KZR) stock does not pay dividends to its shareholders as of June 14, 2024.

When is the next Kezar Life Sciences dividend payment date?

Kezar Life Sciences (KZR) stock does not pay dividends to its shareholders.

What is the beta indicator for Kezar Life Sciences?

Kezar Life Sciences (KZR) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Kezar Life Sciences stock price target?

The target price for Kezar Life Sciences (KZR) stock is $11.67, which is NaN% below the current price of $. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Kezar Life Sciences stock

Buy or sell Kezar Life Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing